MC
BEAM icon

Moors & Cabot’s Beam Therapeutics BEAM Stock Holding History

Moors & Cabot’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,770
Closed -$216K – 826
2022
Q1 		$216K Hold
3,770
– – 0.01% 747
2021
Q4 		$300K Buy
3,770
+100
+3% +$8.56K 0.02% 631
2021
Q3 		$320K Sell
3,670
-500
-12% -$50.2K 0.02% 576
2021
Q2 		$537K Buy
4,170
+1,170
+39% +$93.2K 0.04% 399
2021
Q1 		$240K Hold
3,000
– – 0.02% 617
2020
Q4 		$246K Buy
+3,000
New +$148K 0.02% 580

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Moors & Cabot's BEAM Position: Q2 2022 in Review

Moors & Cabot sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 3,770 shares — an estimated $216K sold.

Moors & Cabot first reported a position in BEAM in Q4 2020 and held it in 6 quarters. The position peaked at $537K in Q2 2021. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • Moors & Cabot reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Moors & Cabot sold 3,770 Beam Therapeutics shares in Q2 2022, an estimated $216K.
  • Moors & Cabot first reported a position in Beam Therapeutics in Q4 2020 and held it in 6 quarters.
  • Moors & Cabot's Beam Therapeutics position peaked at $537K in Q2 2021.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on Moors & Cabot's 13F filing for Q2 2022, filed 8 Aug 2022.